Janssen presents wealth of new data on Imbruvica at EHA

14 June 2016

Janssen-Cilag International, a European subsidiary of US health care giant Johnson & Johnson (NSYE: JNJ) has presented a wealth of new data at the 2016 European Hematology Association (EHA) Congress in Copenhagen, including 52 abstracts on Imbruvica (ibrutinib).

Key studies investigate the long-term effectiveness and target populations for Imbruvica in treating chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The key findings presented at the 2016 EHA Congress include:

Long-term use of ibrutinib in the treatment of relapsed/refractory CLL

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK